Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
331. |
ECCT/17/08/07 | Tambua Mapema Plus Impact of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection and reduce HIV transmission – Tambua Mapema Plus |
Principal Investigator(s) 1. Eduard J Sanders 2. Susan M Graham Site(s) in Kenya KEMRI Mtwapa Research Clinic |
View |
332. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
View |
333. |
ECCT/17/08/02 | IMPROVE (Improving PRegnancy Outcomes with intermittent PReVEntive treatment in Africa) IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine resistance areas in Kenya, Malawi and Tanzania: an international multi-centre 3-arm placebo-controlled trial |
Principal Investigator(s) 1. Simon Kariuki Site(s) in Kenya 1. Migori County Referral Hospital (Migori county) 2. Homa Bay County Referral Hospital (Homa Bay county) 3. Rongo Sub-County Hospital (Migori county) 4. Ahero Sub-County Hospital (Kisumu county) 5. Rabuor Sub-County Hospital (Kisumu county) |
View |
334. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
View |
335. |
ECCT/17/08/01 | A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya KEMRI Kilifi |
View |